KalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at HC Wainwright

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $20.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 63.27% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America began coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Trading Down 1.6 %

NASDAQ KALV opened at $12.25 on Friday. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $15.50. The company has a fifty day simple moving average of $9.67 and a two-hundred day simple moving average of $10.30. The stock has a market cap of $605.37 million, a P/E ratio of -3.37 and a beta of 0.76.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares in the company, valued at $2,738,356.10. This trade represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, with a total value of $382,873.32. Following the acquisition, the insider now directly owns 4,986,480 shares in the company, valued at $43,681,564.80. This trade represents a 0.88 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. 10.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 1,319 shares in the last quarter. HighVista Strategies LLC lifted its position in shares of KalVista Pharmaceuticals by 4.5% in the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after acquiring an additional 1,432 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. raised its stake in KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).